本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SEOUL, South Korea, Feb. 11, 2026 /PRNewswire/ -- CJ Foods, a global leader in Korean, Asian and American cuisine, and the food business unit of CJ CheilJedang, today announced the appointment of Adam Ricciardone as its new Global Chief Technology Officer (CTO). Adam Ricciardone, Global CTO of CJ Foods With more than 30 years of experience as a global R&D executive across the FMCG and consumer health industries, Ricciardone brings deep expertise leading innovation across Asia-Pacific, North America and Europe. His track record of aligning technical innovation with strong commercial outcomes will support CJ Foods as it continues to scale its global portfolio and strengthen R&D competitiveness. As Global CTO, Ricciardone will lead CJ Foods' global growth agenda centered on bibigo Global Strategic Products (GSP). In this role, he will establish a global R&D strategy roadmap grounded in evolving food industry trends, enhance CJ Foods' differentiated technology competitiveness, and build a cross-regional collaboration system to generate stronger global synergies across Regional R&D organizations. "We are pleased to welcome Adam to CJ Foods as Global CTO," said Dr. Gregory Yep, Global CEO of CJ Foods. "With the bibigo brand continuing to gain momentum with consumers worldwide, Adam's depth of experience and proven ability to translate R&D excellence into business impact will be instrumental as we further strengthen our global innovation capabilities and build a world-class R&D organization." Prior to CJ Foods, Ricciardone served as Global Head of R&D, Skin Health & Beauty at Kenvue, where he led enterprise innovation and improved business profitability. In particular, he established cross-functional collaboration and change management processes that shortened new product launch timelines and rapidly reset technology roadmaps to prioritize business viability. Previously, he spent nearly three decades at Johnson & Johnson, including as Head of R&D, Consumer Health Asia-Pacific. Ricciardone holds a Master of Business and Technology and a Bachelor of Science in Industrial Chemistry from The University of New South Wales. About CJ Foods CJ Foods, a business unit of CJ CheilJedang, is a global food company delivering a variety of products ranging from foodstuffs and frozen/chilled foods to appetizers. As the largest food company in Korea for decades, CJ Foods is now leading the global food industry with its renowned Korean food brand "bibigo." Under bibigo, it offers delicious K-food products including Mandu (Korean-style dumpling), chicken, processed rice, Korean sauce, Kimchi, Gim (seaweed), roll, and K-street food. The company operates in multiple regions worldwide including South Korea, the U.S. (as CJ Schwan's), Japan, China, Southeast Asia, Europe, and Oceania. For more information, visit https://www.cj.co.kr/en/aboutus/business/food
***NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES.*** Vancouver, British Columbia - Newsfile Corp. - February 10, 2026 - Railtown AI Technologies Inc. (CSE: RAIL) ("Railtown" or the "Company"), a Canadian company building advanced AI developer and agentic platforms, announces that Mike Lazaridis, co-founder of Research In Motion (now known as BlackBerry), has joined Railtown's Advisory Board and along with fellow co-founder Doug Fregin, is leading a $3.4 million private placement in Railtown (the "Private Placement"), further supporting the company's growth and mission to develop Canadian AI talent and technology. The Private Placement consists of up to 11,333,334 units of the Company (each, a "Unit") at a price of $0.30 per Unit, with each Unit comprised of one common share in the capital of Railtown (each, a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant is exercisable into one (1) Share at a price of $0.45 per Share for a period of 18 months from the date of issuance, subject to acceleration in certain limited circumstances. Mr. Lazaridis and Mr. Fregin are two of Canada's most accomplished technology entrepreneurs who pioneered the modern smartphone industry. They grew Research In Motion from a startup into one of Canada's most successful technology companies with $19 billion in annual revenues, 18,000 employees worldwide, and a peak market value of $68 billion. Railtown's mission, through its Agent Development Platform and collaborations with TELUS and other Canadian AI data hosting providers, is to create a Canadian-focused AI development and deployment ecosystem which aligns closely with both Mr. Lazaridis' and Mr. Fregin's long-standing commitment to building and retaining world-class technology talent in Canada. "Canada develops exceptional talent, but too many feel they have to leave the country to pursue meaningful opportunities," said Mr. Lazaridis. "It's critical that we build companies, platforms, and ecosystems here that allow Canadians to innovate, grow, and compete globally. Railtown is building foundational AI technology in Canada, and I'm excited to support that vision." In addition to their entrepreneurial achievements, both Mr. Lazaridis and Mr. Fregin have been a driving force behind Canada's leadership in advanced science and deep technology. Between the two of them, they are founding partners of Quantum Valley Investments, the Institute for Quantum Computing, the Perimeter Institute for Theoretical Physics, and Quantum Valley Ideas Lab - institutions that have helped position Canada as a global centre for quantum research and commercialization. Railtown's focus on Canadian AI sovereignty, including secure, transparent, developer-centric AI infrastructure and agent platforms, closely reflects these values. "Having spent time working in Silicon Valley, I've seen firsthand how powerful a strong technology ecosystem can be," said Cory Brandolini, CEO of Railtown. "In the Valley, many of the most successful founders lead by example-actively investing in the next generation of startups, sharing hard-earned experience, and providing valuable advisory insight. That culture of reinvestment is a major reason the ecosystem continues to thrive." "Mike and Doug's decision to invest in Railtown sends a powerful signal about what's possible when experienced Canadian founders support the next wave of innovation. This investment, along with Mike's involvement on the Advisory Board will add invaluable strategic guidance, reinforcing Railtown's mission to build a globally competitive AI company from Canada." As described above, the Warrants issuable in Private Placement are subject to acceleration such that if, during a period of 10 consecutive trading days prior to their expiry date, the daily volume-weighted average trading price of the Shares on the Canadian Securities Exchange (the "CSE") or such other stock exchange where the majority of the trading volume occurs, exceeds $0.90 for each of those 10 consecutive days, the Company may, within 30 days of such an occurrence, give written notice to the holders of the Warrants that the securities will expire at 5:00 p.m. (Vancouver time) on the 30th day following the giving of notice unless exercised by the holders prior to such date. Any Warrants which remain unexercised at 5:00 p.m. (Vancouver time) on the 30th day following the giving of such notice will expire at that time. The Company intends to use the proceeds of the Private Placement for general working capital purposes and may pay finder's fees to eligible finders in the form of cash and/or common share purchase warrants. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the CSE. All securities issued in connection with the Private Placement will be subject to a standard hold period of four months and one day in accordance with applicable Canadian securities laws. None of the securities referenced in this news release have been or will be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any applicable state securities laws and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) or persons in the United States absent registration or an applicable exemption from such registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About Railtown Railtown AI Technologies Inc. builds AI developer tools and agentic frameworks that power the next generation of intelligent applications. Its Platform - including real-time ingestion (Railengine), agent development frameworks (Railtracks ADK), and advanced observability (Conductr) - helps teams build, deploy, and operate AI agents with confidence and at scale. For more information, visit www.railtown.ai. Follow us on social media LinkedIn: https://www.linkedin.com/company/railtown-ai/ SUBSCRIBE FOR INVESTOR NEWS Click here to receive our latest investor news alerts. ON BEHALF OF THE BOARD "Cory Brandolini" Cory Brandolini, Chief Executive Officer INVESTOR CONTACT Rebecca Kerswell Investor Relations Contact Email: investors@railtown.ai Phone: 1-604-417-4440 This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will," "may", "should", "intends", "anticipates", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the anticipated closing of the Private Placement, the use of proceeds from the Private Placement, and the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulators. Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law. The issuer is solely responsible for the content of this announcement.
SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- As China's new drug R&D enters the "deep waters" of homogeneous competition, the path for followers has become increasingly crowded. Target congestion, rising costs, and intensifying global races have pushed the traditional follow-on model to its limits. The industry must pivot—returning to the very starting point of innovation. Yet a critical question remains: how can scientific discoveries cross the "Valley of Death" of industrial translation? How can a sustainable ecosystem of original innovation be continuously cultivated? The answer lies not in isolated efforts, but in cross-disciplinary co-creation. Against this backdrop, Sanyou Bio, in partnership with Tongxieyi, jointly hosted the "2026 China New Drug Source Innovation Forum" on February 8, 2026, in Shanghai. The forum bought together visionary leaders from academia, industry, and the investment communities to explore breakthrough pathways for source innovation in new drug development and to envision the future of the biopharmaceutical industry. The forum addressed cutting-edge fields and topics ranging from AI-driven drug discovery and personalized immunotherapies, to next-generation ADC design and human micropeptidome research; from university–industry translational collaboration to asset value re-evaluation. Under the theme "Nurturing Innovation at Its Source", this intellectual gathering served as a platform for cross-sector collaboration, while also witnessed the official launch of the Clicklinks Innovation Hub for Original Drug Discovery, and the signing of multiple strategic partnerships. The forum was fully livestreamed on Tongxieyi's WeChat Channel and WeChat Mini Program with online viewership exceeding 30,000. 01 | Opening Address Kai-Xian ChenResearch Fellow, Shanghai Institute of Materia Medica, Chinese Academy of Sciences China's biopharmaceutical industry has evolved from a model dominated by generic-drug to one increasingly driven by breakthroughs in original innovation medicines. Supported by strong national policies, it has emerged as an important growth engine of global pharmaceutical innovation. Original innovative drugs now represent the core driving force of industry development and a key pillar of the Healthy China strategy. Nevertheless, challenges remain in areas such as source innovation, core technologies, translational efficiency, and industry–academia collaboration. These challenges call for concerted efforts across the entire ecosystem. The development of original innovative medicines relies on the integration of advanced technologies, enabling platforms, high-level talent, and close collaboration among industry, academia, and research institutions. The Shanghai Institute of Materia Medica, Chinese Academy of Sciences is committed to deepening cooperation with all stakeholders, focusing on major disease areas, and driving the industry's transition from "following" to "running alongside" and ultimately "leading" global innovation. Through these efforts, we aim to support the globalization of China's homegrown innovative biologics and promote the high-quality industry development. 02 Keynote Presentations Guojun LangFounder & CEO, Sanyou Bio Making Innovative Biologic Drug Development Accessible to All Over the past decade, Sanyou Bio has remained deeply committed to the development of innovative biologics. Anchored by its intelligent Super-Trillion Antibody Library (STAL), now exceeding 11 trillion in library compacity, and proprietary AI-STAL technology, the company has built an integrated, intelligent R&D platform that seamlessly combines wet-lab and dry-lab capabilities. This platform underpins a dual-engine growth model driven by R&D innovation and commercial operations. To date, Sanyou Bio has served over 2,000 clients worldwide and delivered over 2,000 projects. Among more than 60 collaborative programs, over 10 have successfully completed IND (Investigational New Drug) filings, and three have advanced to Phase III clinical trials. Looking ahead, Sanyou Bio will advance its "5-5 Strategic Initiative", leveraging the combined power of AI technologies and super-trillion-scale libraries, to establish the Clicklinks Innovation Hub for Original Drug Discovery. Through close collaboration with government, industry, academia, research institutions, and healthcare partners, Sanyou Bio aims to build a robust innovation ecosystem – advancing its mission of "Making innovative biologic drug development accessible and achievable for all". Hua MaoPartner & Managing Director, Greater ChinaFrost & Sullivan Global Innovative Drug Market Overview Driven by multiple factors such as regulatory reform in drug approval and increased capital investment, China has seen a rapid surge in the number of innovative drugs under development. China has now surpassed Europe to become the world's second-largest hub for innovative drug pipelines, trailing only the United States. At the same time, pipeline quality has improved significantly, with a rising proportion of First-in-Class (FIC) assets, particularly in advanced therapies such as cell and gene therapies (CGT) and nucleic acid-based drugs. Although global and Chinese biotech investment and financing activity in innovative drugs has experienced fluctuations, biologics—including monoclonal antibodies, ADCs, and CGT— have remained highly favored. In China business development and licensing transaction market remain active, with companies increasingly prioritizing internationalization strategies. Overall, the industry is characterized by a biologics-driven growth model and an accelerating pace of global Expansion. Zhimin LvAcademician, Academia Europaea University–Industry Collaboration to Advance Translational Research Established in 2014, the Zhejiang University Institute of Translational Medicine is a new-generation research institute dedicated to bridging basic research and clinical medicine and accelerating the industrialization of biologic innovation. The institute operates under a co-construction, co-management, and resource-sharing model in collaboration with seven affiliated hospitals of Zhejiang University School of Medicine, and is supported by a high-caliber multidisciplinary talent team. The institute has achieved significant outcomes in scientific research projects, academic publications, translational achievements, and clinical studies. Through close collaboration with industry partners, it conducts diversified drug R&D programs spanning antibodies, peptides, and small molecules, targeting a wide range of diseases including oncology, metabolic liver diseases, autoimmune disorders, and neurodegenerative diseases. These efforts collectively promote the advancement of pharmaceutical R&D and the sustainable development of the biologic industry. Bin LiResearch Fellow, Shanghai Institute of Immunology Current Status and Future Perspectives of Personalized Immunotherapy Personalized immunotherapy has emerged as a major frontier in oncology. Its therapeutic efficacy is largely determined by the immune characteristics of the tumor microenvironment. Advances in AI and spatiotemporal multi-omics are now providing critical support for improving precision and personalization in immunotherapy. Our research team has long been dedicated to the study of FOXP3+ Treg research and has proposed the Immunological Oscillation Theory. By integrating a multi-omics analytical framework established through tripartite collaboration, we aim to facilitate the translation of Treg-based therapies from fundamental research to clinical application, ultimately contributing to the advent of single-cell–level precision medicine. Tianyi QiuYoung Principal Investigator, Fudan University Accelerating Large-Molecule Drug Discovery and Design with Artificial Intelligence Mutation escape remains a key factor affecting efficacy of antibodies and vaccines. To address three core challenges—immunogenicity prediction, antigen similarity assessment, and high-throughput design and screening—our team has developed the SEPPA series of epitope prediction algorithms and the CE-BLAST antigen similarity prediction algorithm, achieving superior accuracy than conventional tools. We have also established a high-throughput computational workflows, applying it to antibody and vaccine design case studies for SARS-CoV-2, norovirus, and influenza. Experimental validation has confirmed the effectiveness of these designs, resulting in a comprehensive technology pipeline that spans from pathogen analysis to antibody/vaccine discovery and optimization. Hailiang ZhengVice President, R&D, Sanyou Bio Application of AI-STAL in Source Innovation for New Drug Discovery The global antibody drug market is expanding rapidly, and generative AI is increasingly empowering R&D. Traditional antibody discovery, however, faces challenges such as long development cycles. The AI-STAL establishes a comprehensive technology pathway from de novo design to in vitro and in vivo validation, centered on an integrated wet-lab and dry-lab workflow. It is supported by a super-trillion antibody library and an intelligent R&D platform, providing a robust foundation for high-efficiency discovery. Looking ahead, this technology is expected to transform biologics R&D toward precise, on-demand design, accelerating innovation at the very source of new drug development. Xin XieDeputy Director, National Center for Drug Screening New Drug Discovery Targeting G Protein-Coupled Receptors (GPCRs) G protein-coupled receptors (GPCRs) represent the largest family of membrane protein receptors in the human body, playing key roles numerous physiological processes. Dysregulation of GPCR function is closely associated with a wide range of diseases, making GPCRs a central target family in drug discovery. Currently, approximately 30–40% of approved drugs globally target GPCRs, covering therapeutic areas such as neurology, endocrinology, immunology and metabolism. In 2025, sales of GPCR-targeted anti-obesity drugs semaglutide and tirzepatide are each achieved to exceed USD 35 billion, highlighting the substantial value of GPCRs in new drug discovery. The speaker provides an overview of GPCR structure and signal transduction characteristics, as well as new drug screening methodologies. As a case study, GPR84, a GPCR with key role in immune and inflammatory disease, is discussed. This includes research on its functions in colitis, lung injury, and atopic dermatitis, the discovery and optimization of novel structural ligands, and ongoing new drug development efforts targeting colitis and atopic dermatitis. Guoqing CaoChairman, Minghui Pharma Next-Generation ADC Molecule Design The development of innovative drugs is inherently long and high-risk, relying on scientific innovation, technological support, outstanding teams, and perseverance. ADC represents a major breakthrough in cancer therapy, now expanding from hematologic malignancies to solid tumors. Their rapid development is driven by multidimensional technological upgrades, including targets, targeting agents, linkers, and payloads. Minghui's SuperTopoi ADC platform demonstrates significant advantages, featuring highly efficient proprietary payloads, clinically validated linkers, and optimized antibody engineering, achieving strong safety profiles and antitumor efficacy. Among its lead candidates, MHB088C has shown remarkable efficacy and excellent safety and tolerability across multiple tumor clinical studies, with a favorable benefit-risk profile, and its clinical development is progressing steadily. Yujie XiaProduct Director, Sanyou Bio Launch of Clicklinks Original Innovative Drug Innovation Hub The Clicklinks Original Innovative Drug Innovation Hub is founded on the principles of openness and efficiency, industry collaboration, mutual benefit and win-win outcomes, and value realization. It is committed to building a sustainable platform that integrates upstream and downstream partners and accelerates the translation of research outcomes. Powered by AI-STAL, the Clicklinks focuses on nine major disease areas and over ten types of innovative molecular modalities, ensuring precise alignment with unmet clinical needs. Its development aims to foster global ecosystem collaboration and establish deeply integrated strategic partnerships, supporting partners in the continuous development of original innovative drugs. Our vision is to cultivate a thriving "Innovation Rainforest", where an open ecosystem empowers partners across all dimensions of drug discovery and development. 03 Signing Ceremony The vitality of source innovation lies not only in breakthroughs in cutting-edge science, but also in the smooth translation from laboratory research to industry and the co-building of an innovation ecosystem. At this forum, the "AI-STAL–Driven Clicklinks Original Innovative Drug Innovation Hub Signing Ceremony" was officially held with great prominence. Fourteen distinguished representatives from academia and industry jointly took the stage to witness this milestone. They are: Hongchen Gu: President, Hefei Early Screening Institute, Shanghai Jiao Tong UniversityNaping Tang: Vice President, InnoStarWeiqin Ni: Deputy General Manager, LiferiverKai Tan: General Manager, Dragon Sail PharmaceuticalShumin Wang: General Manager, TransRecoHenghao Xu: General Manager, Yugong BioLinglong Zou: General Manager, Kanwhish BiotechFeng Tan: General Manager, NovoProGuozhen Xing: General Manager, AnLing BiomedZhenghai Li: General Manager, NephroMedicineDongxiao Feng: Deputy General Manager, Shanghai Model Organisms Center (SMOC)Donglin Sun: Deputy General Manager, AcemabYichun Luo: Medical Director, RevvityGuojun Lang: Founder & CEO, Sanyou Bio 04 Roundtable Dialogues Entrepreneurs and Scientists in discussion on the Ecosystem of Original Innovative Drug R&DZhenze Hu (Moderator): Founder, ZhenSightiDongzhou Liu: Chief Strategy Officer (CSO), Huadong MedicineQi He: Co-Founder & CEO, TandemAIYiwei Chu: Professor, Fudan University, Vice President, Chinese Society of Immunology (CSI)Xuanhui Xie: Managing Partner, TVM Capital / ValueSeek VenturesYongqi Chen: Founder & CEO, ResprolySunxing Qin: Chairman, LePure Biotech China's ecosystem for innovative drugs has taken shape and already demonstrates significant achievements. Strengths are particularly notable in CRO/CDMO services and early-stage R&D, with active outbound licensing and collaboration. However, several key gaps remain. Payment and reimbursement systems are underdeveloped, translational pathways from basic research to Proof of Concept (POC) are incomplete, and there is a shortage of talent, insufficient global commercialization capabilities, and limited collaboration across the industry chain. In terms of early-stage innovation risk, the translation of academic research remains challenging, necessitating coordinated efforts among enterprises, investors, and government. Large pharmaceutical companies are increasingly willing to engage in breakthrough early-stage projects. On the non-technical side, low tolerance for failure, decision-making inefficiencies, and misallocation of resources have created competitive "overwork" pressure, which hinder ecosystem efficiency. Over the next 5–10 years, the ecosystem is expected to enter a phase of optimization, integration, and deeper globalization. Recognition of clinical data will increase, differentiated innovation will become mainstream. China is poised to produce globally leading pharmaceutical companies, achieving a leap from high competition to high-quality innovation. Source Innovation and the Re-Evaluation of China's Innovative Drug AssetsZengjiang Cheng (Moderator): Vice Chairman, China Pharmaceutical Industry Promotion Association Founder & Chairman, TongxieyiTao Ru: Managing Director, Shanghai Guotou Pioneer Private Equity FundJian'er Yao: Chairman, Tellgen CorporationYu Zhou: Partner, Huatai Zijin FundJia Li: Partner, Longshine InvestmentJie Chen: Expert, Technology Finance DepartmentBank of CommunicationsSuyang Wang: General Manager, Technology Finance Division Shanghai Rural Commercial Bank China's innovative drug assets have transitioned from imitation to differentiated, engineering-driven innovation, attracting growing international attention. BD transaction upfront payments have grown counter-cyclically. Nevertheless, challenges remain, including homogeneous competition, valuation dependence on oversea markets, and tighter Hong Kong IPO policies, making high-quality differentiated assets the core of the market. On the international front, supply is increasing, but clinical value and differentiation remain critical. Overseas companies often acquire Chinese assets for efficiency reasons, highlighting the need to enhance global commercialization capabilities in the long term. From a capital perspective, investment institutions urge the market to avoid following trends, remain patient, and focus on first-in-class innovation. Banks are supporting innovative drugs across the full chain through credit loans, equity-linked products, and clinical loans, emphasizing early evaluation of team and data, and in some cases reducing personal joint liability. These measures provide both timely support and strategic capital reinforcement, making financial backing more effective and targeted. In terms of source innovation, universities and research institutes focus on fundamental target discovery, while enterprises lead engineering-based translation and implementation. Effective industry–academia–research collaboration, along with tolerance for innovation risk, is essential to foster a healthy and sustainable ecosystem. 05 Closing Remarks Zengjiang ChengVice Chairman, China Pharmaceutical Industry Promotion AssociationFounder & Chairman, Tongxieyi The forum featured nine keynote presentations and two roundtable discussions, bringing together leading experts from China's top scientific institutions and universities. In-depth exchanges focused on global new drug R&D, AI-driven drug discovery, next-generation ADC technologies, and personalized medicine, highlighting China's positive trajectory from "following" to "running alongside" and even "leading" in these cutting-edge fields. Notably, significant internationally competitive achievements and teams have emerged in key areas such as AI-driven drug development and precision medicine. During the forum, Sanyou Bio signed strategic agreements with multiple partners to officially launch the Clicklinks Innovative Drug Innovation Hub, marking a major step forward in industry–academia–research collaboration. We look forward to Sanyou Bio achieving new milestones over the next decade, supporting the next wave of innovation in China's biopharmaceutical innovation. Wishing everyone success and momentum in the Year of the Horse. About Sanyou Sanyou Biopharmaceuticals is a high-tech biopharmaceutical enterprise driven by its super-trillion molecule library and artificial intelligence technology, with the mission of "making innovative biologics R&D easy for clients worldwide". Sanyou Bio has been dedicated to developing a world-class innovative biological drug R&D hub. The company is centered on its AI-driven super-trillion antibody library (AI-STAL) and supported by its world-leading, integrated and intelligent R&D platform for innovative biologics development that seamlessly combines in silico and wet-lab capabilities. Sanyou drives the global development and industrialization of innovative new drugs through diversified business models. Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities. Sanyou has established strong collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50 collaboration projects, over 10 of which have advanced to IND approval and clinical development stages. The company has filed over 130 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai "Specialized and Innovative" Enterprise, ISO9001, and ISO27001.
SINGAPORE - Media OutReach Newswire - 10 February 2026 - MSIG Singapore has been named Digital Insurer of the Year at The Asset Triple A Digital Finance Awards 2026. The Asset Triple A Digital Finance Awards stand as a prestigious benchmark in the industry, celebrating trailblazing innovation and outstanding digital experiences that redefine customer engagement. Over the past year, MSIG Singapore has delivered strong financial results that has seen a double-digit increase in retail customers and policy count from online channels. The company has also strengthened its digital proposition by broadening its suite of personal lines products, designing solutions guided by deep customer insights and data‑driven analytics. Strategic partnerships and tie-ups have also further boosted insurance accessibility and value proposition to its customers. Through the adoption of Generative AI and RPA-driven straight-through processing, the company has elevated both service quality and operational excellence. These advancements have delivered substantial productivity gains, saving over 31,000 hours annually and have enabled twenty percent of travel claims to be automatically approved and paid within 48 hours. Commenting on the award, Steven Leong, Head of Retail Distribution, MSIG Singapore, said "This recognition is a testament to the unwavering dedication of our people, and we are grateful to our business partners whose support has enabled us to scale new heights once again. This award not only celebrates how far we have come but also strengthens our ambition to advance MSIG's leadership as a digital‑first insurer in Singapore." Hashtag: #MSIGSingaporeThe issuer is solely responsible for the content of this announcement.About MSIG InsuranceA leading general insurer with a local presence of over 100 years, MSIG Singapore offers an extensive range of insurance solutions for commercial and personal risk protection, enabling the security and safety of individuals and businesses. MSIG Singapore holds an A+/Stable financial rating by Standard & Poor's. MSIG Singapore has garnered numerous awards for delivering digitally innovative and customer-centric solutions. The company was named 'Best General Insurer for Singapore' by InsuranceAsia News and was awarded 'Personal Lines Insurer of the Year' and 'Underwriting Excellence' by Re(in) Asia. MSIG is a subsidiary of Mitsui Sumitomo Insurance Co., Ltd, and a member of the MS&AD Insurance Group – one of the largest general insurance groups in the world with presence in 50 countries and regions globally, 18 of which are in Asia Pacific including all ASEAN markets as well as in Australia, New Zealand, China, Hong Kong, Taiwan, South Korea and India. Headquartered in Japan, MS&AD is amongst the top non-life insurance groups in the world based on gross revenue.
BANGKOK, Feb. 10, 2026 /PRNewswire/ -- Researchers at Chulalongkorn University are redefining the role of Thai silk by developing silk protein into a versatile platform for medical products, aiming to reduce Thailand's reliance on imported biomaterials while creating sustainable income for farmers. Silklife: Chula Researchers Transform Thai Silk into Medical Innovation The Silklife research project, led by Associate Professor Dr. Juthamas Ratanavaraporn of the Faculty of Engineering, converts silk protein into various medical applications, including pain-relief and sleep-aid patches, artificial tissues, and injectable joint gels. The initiative addresses a key challenge facing Thailand's rapidly expanding medical industry, which still depends heavily on imported materials such as collagen and hyaluronic acid. Thai silk, traditionally valued as a cultural heritage textile, possesses unique biomedical properties. Its primary protein, fibroin, is naturally strong, biocompatible, and safely degrades into amino acids in the body. Unlike silk from other countries, Thai silk has a natural golden hue and a hydrophobic molecular structure, enabling it to bind effectively with certain drug compounds and making it suitable for targeted drug delivery systems. The Silklife project adopts a comprehensive approach spanning the entire value chain. The research team established an organic silkworm farming model on five rai of land in Ratchaburi province, certified under Thailand's organic agriculture standards. Controlled, closed-system rearing facilities—certified under Thai Agricultural Standard 8203—ensure consistent quality year-round. Contract farmers are trained to follow strict operating procedures to minimize contamination. High-quality cocoons are processed at a pilot plant meeting ISO 13485 manufacturing standards and ISO 10993 medical safety standards. Achieving medical-grade silk protein requires three to four years of development from upstream farming to midstream processing. Initial products focus on external use to build safety and market confidence, including hydrogel skin patches that release herbal pain-relief compounds for up to eight hours, and CBD sleep patches designed as an alternative to high-dose oral administration. More advanced applications include biodegradable scaffolds for dental and tissue regeneration and injectable silk-based joint gels now entering early-stage clinical trials at King Chulalongkorn Memorial Hospital. Beyond medical innovation, the project delivers economic impact. Participating farmers can sell medical-grade silk cocoons at prices several times higher than conventional market rates. Researchers emphasize that Silklife's platform approach allows a single material to be developed into dozens of products, positioning Thai silk as a competitive, homegrown alternative in global medical markets. For more information, visit www.enginelife.co.th Read the full article at: https://www.chula.ac.th/en/highlight/285235/ About Chulalongkorn University Chulalongkorn University has made the world's top 50 university list for employment outcomes, which reflects both the high employment rate and work ability of Chula graduates. The university is also listed as the best in Thailand for the 15th Consecutive Year (since 2009), according to the newly released QS World University Rankings 2024, putting Chula at 211th in the world, up from 244th last year. Social Media: Facebook: https://www.facebook.com/ChulalongkornUniversityYoutube: https://www.youtube.com/chulauniversityLinkedin: https://www.linkedin.com/school/15101896/
CHENNAI, India, Feb. 6, 2026 /PRNewswire/ -- India's top-ranked higher education, the Indian Institute of Technology Madras (IIT Madras), has established a new entity, IIT Madras Global Research Foundation (IITM Global) with a charter to take IIT Madras' research and innovation ecosystem into multiple geographies. Indian External Affairs Minister Dr S Jaishankar (3rd L) releases a book on ‘India’s Innovation Ecosystem Going Global’ on 2 Jan at IITM, India IITM Global is strengthening its engagement in Southeast Asia through strategic partnerships in Malaysia. IITM Global was newly-launched by Dr. S. Jaishankar, Hon'ble Minister of External Affairs, Government of India. The initiative supports IIT Madras's vision to become the world's first multinational university by positioning it as a globally networked hub for education, research, innovation and entrepreneurship. Addressing the IITM Global launch event at IIT Madras Campus on 2nd Jan 2026, Dr. S. Jaishankar said, "An IIT Madras Campus in Tanzania is a way by which Indian Foreign Policy has leveraged the capabilities of an Institution here to make a huge impact. In ten years from now, think how many Students of Africa would have passed through its portals. We are a human resource power and we should play to our strengths. We now have the capability to start doing so. When institutions of excellence in the country start going abroad, the business of foreign policy gains a huge addition to our arsenal. This is something very transformational." As part of its Malaysia-focused expansion, IIT Madras has entered into a collaboration with ASEM (Advanced Semiconductor Academy of Malaysia) to deepen academic cooperation and innovation-led engagement in the region. The partnership will focus on delivering joint certification programs, enabling student exchange and faculty mobility, and supporting education and skilling initiatives tailored to Malaysian and regional needs with a focus on Semiconductors & Semiconductor design. In addition, the partnership envisions setting up an Overseas Research Centre in Malaysia to support high-potential deep-tech startups seeking to expand into the Southeast Asian market. IITM Global has also formalised a collaboration framework with Aisling Group. The partnership is designed to build synergies aligned with IITM Global's mission to internationalise Indian innovation, technology and startups. Areas of collaboration include startup scaling support, Skilling and short term certification programs, collaborative research initiatives, and intellectual property and technology transfer, enabling closer integration between Indian and Malaysian innovation ecosystems. IITM Global has been conceived as a strategic, scalable 'plug-and-play' platform that enables researchers, students, startups and industry partners to access global markets, capital and collaborative research opportunities. Widely recognised as India's top-ranked institution for higher education, IIT Madras is ranked #1 Overall and #1 Engineering Institute in India's National Institutional Ranking Framework (NIRF), #180 in the QS World University Rankings and #56 in the QS Asian University Rankings. The institute brings a strong research ecosystem to its global partnerships, comprising 18 academic departments, 15 Centres of Excellence, 23 research centres and nearly 100 advanced laboratories, supported by more than 650 faculty members and over 10,000 students.
A12 藝術空間
Innovation
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
